GeoVax Labs Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

Atlanta, GA - May 1, 2025 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company focused on developing human vaccines and immunotherapies against infectious diseases and cancer, announced its financial results and key operational accomplishments for the quarter ended March 31, 2025. Despite the recent termination of its Project NextGen award by the Biomedical Advanced Research and Development Authority (BARDA), GeoVax remains committed to advancing its next-generation, multi-antigen COVID-19 vaccine, GEO-CM04S1. This vaccine continues to show promise and is expected to progress with additional data evaluating its use as a booster to mRNA vaccines in healthy adults in the second quarter of 2025.

The company also announced that the clinical evaluation of its vaccine candidate, GEO-MVA, aimed at providing protection against Mpox and Smallpox, is expected to initiate in the second half of 2025. Additionally, GeoVax’s gene-directed enzyme prodrug therapy, Gedeptin®, is advancing into a Phase 2 clinical trial as a treatment for first recurrent head and neck cancer in combination with an immune checkpoint inhibitor.

GeoVax is set to host a conference call today at 4:30 p.m. ET to discuss these updates in detail.

GeoVax Presents Gedeptin(R) Clinical Data at AACR Annual Meeting

Atlanta, GA - April 29, 2025 - GeoVax Labs, Inc. (Nasdaq: GOVX) announced the presentation of new clinical data on its gene-directed enzyme prodrug therapy, Gedeptin®, at the American Association for Cancer Research (AACR) Annual Meeting 2025, held in Chicago, IL. The presentation, titled “Viral-Vectored, Gene-Directed Prodrug Therapy (Gedeptin) in Needle-Accessible Solid Tumors,” was delivered by J. Marc Pipas, M.D., Executive Medical Director, Oncology at GeoVax, during the Phase II Clinical Trials 1 Poster Session.

The session attracted significant interest from researchers and clinicians, highlighting the growing recognition of Gedeptin’s therapeutic potential. The corresponding abstract was published in the AACR journal Cancer Research, underscoring the promising results of Gedeptin in treating solid tumors.

Company Overview

GeoVax Labs Inc. is a biomedical company specializing in the development, manufacturing, testing, conducting human trials, licensing, and commercializing human vaccines for diseases caused by HIV-1 (AIDS) and other infectious agents. The company is listed on the Nasdaq under the ticker symbol GOVX. As of April 29, 2025, GeoVax’s close price was $1.01, with a market capitalization of $13,840,000. The company’s 52-week high was $11.18 on August 18, 2024, and its 52-week low was $0.73 on April 14, 2025. The price-to-earnings ratio stands at -0.399371, reflecting the company’s current financial performance.